1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Valneva SE
  6. News
  7. Summary
    VLA   FR0004056851

VALNEVA SE

(VLA)
  Report
Real-time Euronext Paris  -  11:35 2022-08-19 am EDT
9.724 EUR   -1.84%
08/18Valneva Starts Rolling Submission Of US FDA Biologics License Application For Chikungunya Vaccine
MT
08/18French Drugmaker Valneva's COVID-19 Jab Gets WHO Recommendation
MT
08/18Valneva Initiates Rolling Submission of US FDA Biologics License Application for Chikungunya Vaccine
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer Completes 8% Stake Purchase in French Vaccine Maker Valneva

06/23/2022 | 11:07pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
PFIZER, INC. 1.17% 49.15 Delayed Quote.-16.77%
VALNEVA SE -1.84% 9.724 Real-time Quote.-60.31%
All news about VALNEVA SE
08/18Valneva Starts Rolling Submission Of US FDA Biologics License Application For Chikungun..
MT
08/18French Drugmaker Valneva's COVID-19 Jab Gets WHO Recommendation
MT
08/18Valneva Initiates Rolling Submission of US FDA Biologics License Application for Chikun..
MT
08/18Valneva Initiates Rolling Submission of FDA Biologics License Application for its Singl..
GL
08/18Valneva Initiates Rolling Submission of FDA Biologics License Application for its Singl..
AQ
08/18Valneva SE Initiates Rolling Submission of U.S. Food and Drug Administration Biologics ..
CI
08/18Valneva's COVID-19 Vaccine Recommended for Use by World Health Organization
MT
08/18WHO recommends Valneva's COVID vaccine
RE
08/18WHO recommends Valneva's COVID vaccine
RE
08/18Valneva Says Pentagon Didn't Exercise 2nd Option Year of Supply Contract for Japanese E..
MT
More news
Analyst Recommendations on VALNEVA SE
More recommendations
Financials
Sales 2022 339 M 341 M 341 M
Net income 2022 -26,4 M -26,5 M -26,5 M
Net cash 2022 220 M 221 M 221 M
P/E ratio 2022 -41,4x
Yield 2022 -
Capitalization 1 140 M 1 144 M 1 144 M
EV / Sales 2022 2,71x
EV / Sales 2023 3,37x
Nbr of Employees 700
Free-Float 68,2%
Chart VALNEVA SE
Duration : Period :
Valneva SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VALNEVA SE
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 6
Last Close Price 9,72 €
Average target price 15,82 €
Spread / Average Target 62,7%
EPS Revisions
Managers and Directors
Thomas Lingelbach President & Chief Executive Officer
Franck Charles Marie Grimaud Director General & Chief Business Officer
Peter Buhler Chief Financial Officer
Frédéric Grimaud Chairman-Supervisory Board
Michael Möhlen Vice President-Technical Development
Sector and Competitors
1st jan.Capi. (M$)
VALNEVA SE-60.31%1 144
MODERNA, INC.-40.94%58 680
LONZA GROUP AG-24.63%44 689
IQVIA HOLDINGS INC.-15.28%44 542
SEAGEN INC.11.04%31 186
ALNYLAM PHARMACEUTICALS, INC.31.77%26 820